BIIB
Price
$132.22
Change
-$0.43 (-0.32%)
Updated
Aug 29 closing price
Capitalization
19.39B
52 days until earnings call
GILD
Price
$112.97
Change
+$0.41 (+0.36%)
Updated
Aug 29 closing price
Capitalization
140.17B
54 days until earnings call
Interact to see
Advertisement

BIIB vs GILD

Header iconBIIB vs GILD Comparison
Open Charts BIIB vs GILDBanner chart's image
Biogen
Price$132.22
Change-$0.43 (-0.32%)
Volume$1.08M
Capitalization19.39B
Gilead Sciences
Price$112.97
Change+$0.41 (+0.36%)
Volume$4.63M
Capitalization140.17B
BIIB vs GILD Comparison Chart in %
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. GILD commentary
Aug 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a StrongBuy and GILD is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 31, 2025
Stock price -- (BIIB: $132.22 vs. GILD: $112.97)
Brand notoriety: BIIB and GILD are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 79% vs. GILD: 73%
Market capitalization -- BIIB: $19.39B vs. GILD: $140.17B
BIIB [@Pharmaceuticals: Major] is valued at $19.39B. GILD’s [@Pharmaceuticals: Major] market capitalization is $140.17B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.73B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileGILD’s FA Score has 3 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • GILD’s FA Score: 3 green, 2 red.
According to our system of comparison, GILD is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 5 TA indicator(s) are bullish while GILD’s TA Score has 4 bullish TA indicator(s).

  • BIIB’s TA Score: 5 bullish, 4 bearish.
  • GILD’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, GILD is a better buy in the short-term than BIIB.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а -5.09% price change this week, while GILD (@Pharmaceuticals: Major) price change was -1.57% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.73%. For the same industry, the average monthly price growth was +1.44%, and the average quarterly price growth was +12.21%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 22, 2025.

GILD is expected to report earnings on Oct 23, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.73% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GILD($140B) has a higher market cap than BIIB($19.4B). GILD has higher P/E ratio than BIIB: GILD (22.41) vs BIIB (12.65). GILD YTD gains are higher at: 24.034 vs. BIIB (-13.536). GILD has higher annual earnings (EBITDA): 11B vs. BIIB (2.79B). GILD has more cash in the bank: 5.21B vs. BIIB (2.76B). BIIB has less debt than GILD: BIIB (6.6B) vs GILD (24.9B). GILD has higher revenues than BIIB: GILD (28.9B) vs BIIB (10B).
BIIBGILDBIIB / GILD
Capitalization19.4B140B14%
EBITDA2.79B11B25%
Gain YTD-13.53624.034-56%
P/E Ratio12.6522.4156%
Revenue10B28.9B35%
Total Cash2.76B5.21B53%
Total Debt6.6B24.9B26%
FUNDAMENTALS RATINGS
BIIB vs GILD: Fundamental Ratings
BIIB
GILD
OUTLOOK RATING
1..100
1661
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
15
Undervalued
PROFIT vs RISK RATING
1..100
10015
SMR RATING
1..100
7329
PRICE GROWTH RATING
1..100
6151
P/E GROWTH RATING
1..100
9599
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GILD's Valuation (15) in the Biotechnology industry is significantly better than the same rating for BIIB (89). This means that GILD’s stock grew significantly faster than BIIB’s over the last 12 months.

GILD's Profit vs Risk Rating (15) in the Biotechnology industry is significantly better than the same rating for BIIB (100). This means that GILD’s stock grew significantly faster than BIIB’s over the last 12 months.

GILD's SMR Rating (29) in the Biotechnology industry is somewhat better than the same rating for BIIB (73). This means that GILD’s stock grew somewhat faster than BIIB’s over the last 12 months.

GILD's Price Growth Rating (51) in the Biotechnology industry is in the same range as BIIB (61). This means that GILD’s stock grew similarly to BIIB’s over the last 12 months.

BIIB's P/E Growth Rating (95) in the Biotechnology industry is in the same range as GILD (99). This means that BIIB’s stock grew similarly to GILD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBGILD
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
58%
Bullish Trend 2 days ago
61%
Momentum
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
45%
MACD
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
34%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
46%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
57%
Bearish Trend 2 days ago
45%
Advances
ODDS (%)
Bullish Trend 9 days ago
53%
Bullish Trend 20 days ago
59%
Declines
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 3 days ago
48%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
43%
Aroon
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TAGS23.930.07
+0.29%
Teucrium Agricultural Fund
STMZF14.66N/A
N/A
Scottish Mortgage Investment Trust PLC
WTV90.41-0.22
-0.24%
WisdomTree US Value ETF
DAUG42.87-0.16
-0.37%
FT Vest US Equity Deep Bfr ETF Aug
BUL52.86-0.22
-0.42%
Pacer US Cash Cows Growth ETF

GILD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GILD has been loosely correlated with BMY. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then BMY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GILD
1D Price
Change %
GILD100%
+0.36%
BMY - GILD
48%
Loosely correlated
+0.64%
GSK - GILD
42%
Loosely correlated
+0.58%
NVS - GILD
40%
Loosely correlated
+0.06%
AMGN - GILD
40%
Loosely correlated
+0.74%
SNY - GILD
38%
Loosely correlated
-0.92%
More